Recent News
Orphan Drug Status Given to New Treatment for Mesothelioma
A new treatment for mesothelioma was recently given orphan drug status by the United States FDA. The company given orphan drug status is known as Avenge Bio, which is a[…]
Genetic Testing for Mesothelioma
A new study is showing that running genetic tests on mesothelioma patients could be useful. The study was conducted at the University of Chicago and University of Wisconsin. While the[…]
Biomarkers Could be Used to Monitor Mesothelioma Patients
Researchers from Türkiye believe that biomarkers in the blood can help determine if patients are responding well to their treatment. Biomarkers are molecules that can let doctors know what is[…]
New Rules Regarding Reporting of Asbestos
The U.S. Environmental Protection Agency announced its final rule requiring comprehensive reporting of asbestos. The rule requires that importers and manufacturers of asbestos related products report information including use and[…]
PARP Inhibitors Could Soon Help Mesothelioma Patients
There is a new treatment involving PARP inhibitors that could potentially benefit mesothelioma patients. PARP stands for Poly (ADP-ribose) polymerase. PARP is typically involved in repairing damaged DNA in cells.[…]
Marine Bacteria Could Potentially Detoxify Asbestos
There may be a new way to detoxify asbestos. Researchers at the University of Pennsylvania’s Department of Earth and Environmental Science are using bacteria from extreme marine environments. They are[…]
Lawyer for Johnson & Johnson Must Stop Making Unsubstantiated Claims About Potential Settlement
A lawyer for Johnson & Johnson must stop making unsubstantiated claims about support from plaintiffs for an $8.9 billion settlement for talc victims without backing up the claims. The lawyer[…]
CRS-HIPEC for the Treatment of Peritoneal Mesothelioma
Researchers are studying the effectiveness of a multimodal treatment for peritoneal mesothelioma. The therapy involves cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, or CRS-HIPEC. Peritoneal mesothelioma is cancer of the abdominal[…]
Galinpepimut-S and Nivolumab are Effective and Safe for Mesothelioma
The combination of galinpepimut-S and nivolumab is showing promising results for mesothelioma. The study looked at patients who were refractory or relapsed after at least one standard treatment. The combination[…]
Why Patients Quit PIPAC for Mesothelioma
PIPAC, or pressurized intraperitoneal aerosol chemotherapy, is showing promising results for mesothelioma, but patients don’t finish all their sessions. This is a problem because the patients then limit the effectiveness[…]
Skip to content